对于既往合并乙型肝炎病毒（HBV）感染的艾滋病毒感染者，是否应改用长效注射用卡博特韦/利匹韦林：哪些HBV标志物可用于管理HBV再激活风险？
To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?
作者信息
Ollier Laurence, De Monte Anne, Thibault Vincent, Pugliese Pascal, Chirio David, Durant Jacques, Carles Michel, Naqvi Alissa
机构信息
Virology Laboratory, Biological and pathological Center, Nice University Hospital, Nice, France.
Virology Laboratory, Rennes University Hospital, Rennes, France.
出版信息
Open Forum Infect Dis. 2025 May 6;12(6):ofaf266. doi: 10.1093/ofid/ofaf266. eCollection 2025 Jun.
We report the occurrence of low-level hepatitis B virus (HBV) viremia in people with HIV with controlled CD4 counts and isolated core antibody reactivity switched to long-acting injectable cabotegravir/rilpivirine. This series raises questions about the reintroduction of anti-HBV medications, presents the variation of several HBV markers alongside HBV-DNA and reveals an effective spontaneous immune response.
我们报告了在接受长效注射卡博特韦/利匹韦林治疗、CD4计数得到控制且仅核心抗体反应呈阳性的HIV感染者中出现低水平乙型肝炎病毒（HBV）血症的情况。该系列病例引发了关于重新启用抗HBV药物的问题，呈现了几种HBV标志物与HBV-DNA的变化情况，并揭示了一种有效的自发免疫反应。
Zotero 插件